EAST-ASIA PHARMACEUTICAL: Quetiapine raw materials have obtained the raw material drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.EAST-ASIA PHARMACEUTICAL announced that its active pharmaceutical ingredient, Trimebutine, has obtained the registration certificate from the Korean Food and Drug Administration. This medication can be used to treat various symptoms of gastrointestinal motility disorders. It is expected that the national sales of Trimebutine maleate formulations will reach 372 million yuan in 2024. This registration certificate will help the company expand into the Korean market and promote its sales in other overseas markets
According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL (605177.SH) announced that it recently received the active pharmaceutical ingredient registration certificate from the Korean Ministry of Food and Drug Safety (Korea MFDS). Trimebutine has a dual regulatory effect of promoting insufficient gastric motility or inhibiting excessive gastric motility, and can be used to treat symptoms such as loss of appetite, nausea, vomiting, belching, abdominal distension, borborygmi, abdominal pain, diarrhea, and constipation caused by gastrointestinal motility disorders. According to relevant data, the national sales of trimebutine maleate formulations in 2024 are estimated to be approximately 372 million yuan.
The company's trimebutine active pharmaceutical ingredient has obtained the registration certificate in Korea, marking the company's qualification for market entry in Korea, which will have a positive impact on the company's expansion into the Korean pharmaceutical market, thereby promoting the sales of the trimebutine active pharmaceutical ingredient in other overseas markets